TY - JOUR
T1 - 13C-5-FU breath test current status and future directions
T2 - A comprehensive review
AU - Ezzeldin, Hany H.
AU - Acosta, Edward P.
AU - Mattison, Lori K.
AU - Fourie, Jeanne
AU - Modak, Anil
AU - Diasio, Robert B.
PY - 2009
Y1 - 2009
N2 - Breath tests (BTs) represent a safe non-invasive alternative strategy that could provide valuable diagnostic information in conditions like fat malabsorption, carbohydrate (lactose and fructose) malabsorption, liver dysfunction, impaired gastric emptying, abnormal small bowel transit time, small intestinal bacterial overgrowth and Helicobacter pylori infection. To date, despite the availability of a number of breath tests, only three have gained approval by the FDA for application in a clinical setting (13C-urea breath test for the detection of H. pylori; NO breath test for monitoring asthma and alkane breath test for heart transplant rejection). Unfortunately, none of these tests investigate cancer patients or response to cancer chemotherapy. Several years ago it was realized that the presence of a reliable non-invasive approach could assist in the detection of patients at risk of developing severe life-threatening toxicities prior to the administration of fluoropyrimidines (e.g. 5-FU) or related cancer chemotherapy. 5-FU toxicity results mainly from deficient uracil catabolism. This review discusses the development of a BT that utilizes an orally administered pyrimidine ([2-13C]-uracil) which is metabolized via the same catabolic pathway as 5-FU. This ([2- 13C]-uracil) breath test could provide a valuable addition to the patients' standard of care.
AB - Breath tests (BTs) represent a safe non-invasive alternative strategy that could provide valuable diagnostic information in conditions like fat malabsorption, carbohydrate (lactose and fructose) malabsorption, liver dysfunction, impaired gastric emptying, abnormal small bowel transit time, small intestinal bacterial overgrowth and Helicobacter pylori infection. To date, despite the availability of a number of breath tests, only three have gained approval by the FDA for application in a clinical setting (13C-urea breath test for the detection of H. pylori; NO breath test for monitoring asthma and alkane breath test for heart transplant rejection). Unfortunately, none of these tests investigate cancer patients or response to cancer chemotherapy. Several years ago it was realized that the presence of a reliable non-invasive approach could assist in the detection of patients at risk of developing severe life-threatening toxicities prior to the administration of fluoropyrimidines (e.g. 5-FU) or related cancer chemotherapy. 5-FU toxicity results mainly from deficient uracil catabolism. This review discusses the development of a BT that utilizes an orally administered pyrimidine ([2-13C]-uracil) which is metabolized via the same catabolic pathway as 5-FU. This ([2- 13C]-uracil) breath test could provide a valuable addition to the patients' standard of care.
UR - http://www.scopus.com/inward/record.url?scp=72349099452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72349099452&partnerID=8YFLogxK
U2 - 10.1088/1752-7155/3/4/047002
DO - 10.1088/1752-7155/3/4/047002
M3 - Article
C2 - 21386199
AN - SCOPUS:72349099452
SN - 1752-7155
VL - 3
JO - Journal of Breath Research
JF - Journal of Breath Research
IS - 4
M1 - 047002
ER -